Edwards Lifesciences Corp. (NYSE:EW), a leader in transcatheter aortic valve replacement, stands at a pivotal moment as competitive dynamics shift. The company has strengthened following challenges faced by major competitor Medtronic, whose data issues have created market share opportunities. Trading at $85.78, near its 52-week high, the stock reflects investor confidence.
Analysts project Edwards could capture 15%-20% of Medtronic's TAVR market share, drawing parallels to a previous shift when Boston Scientific exited the market. The advantage stems from Medtronic's leadership changes and strategic focus elsewhere. U.S. medical centers prefer Edwards' product reliability.
In January 2026, Edwards canceled its planned acquisition of JenaValve, removing dilution from earnings estimates. The price target was raised to $104, reflecting confidence in organic growth.
During Investor Day in December 2025, Edwards outlined a five-year growth plan emphasizing innovation and pipeline development. The company's strong clinical data from TAVR and TMTT trials supports its market position.
Third-quarter 2025 results exceeded expectations, driven by TAVR upside. However, risks remain: Medtronic is a formidable competitor, and international price sensitivity may limit gains.
Overall, Edwards' diversified pipeline and clinical successes support long-term growth.
